Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 316

1.

Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus.

Crespo N, Illnait J, Más R, Fernández L, Fernández J, Castaño G.

Int J Clin Pharmacol Res. 1999;19(4):117-27.

PMID:
10939029
2.

Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.

Castaño G, Menéndez R, Más R, Amor A, Fernández JL, González RL, Lezcay M, Alvarez E.

Int J Clin Pharmacol Res. 2002;22(3-4):89-99.

PMID:
12837046
3.

Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients.

Castaño G, Más R, Arruzazabala ML, Noa M, Illnait J, Fernández JC, Molina V, Menéndez A.

Int J Clin Pharmacol Res. 1999;19(4):105-16.

PMID:
10939028
4.

Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study.

Castaño G, Mas R, Fernández L, Illnait J, Gámez R, Alvarez E.

Int J Clin Pharmacol Res. 2001;21(1):43-57.

PMID:
11708574
5.

Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia.

Castaño G, Mas R, Fernández L, Illnait J, Mesa M, Alvarez E, Lezcay M.

Drugs Aging. 2003;20(2):153-63.

PMID:
12534315
6.

Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia.

Castaño G, Fernández L, Mas R, Illnait J, Fernández J, Mesa M, Alvarez E, Lezcay M.

Int J Clin Pharmacol Res. 2002;22(2):55-66.

PMID:
12503776
7.

A comparative study of policosanol Versus acipimox in patients with type II hypercholesterolemia.

Alcocer L, Fernández L, Campos E, Más R.

Int J Tissue React. 1999;21(3):85-92.

PMID:
10645516
8.

Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women.

Mirkin A, Mas R, Martinto M, Boccanera R, Robertis A, Poudes R, Fuster A, Lastreto E, Yañez M, Irico G, McCook B, Farré A.

Int J Clin Pharmacol Res. 2001;21(1):31-41.

PMID:
11708573
9.

Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia.

Castaño G, Fernández L, Mas R, Illnait J, Gámez R, Mendoza S, Mesa M, Fernández J.

Drugs R D. 2005;6(4):207-19.

PMID:
16050054
10.

A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study.

Castaño G, Más R, Fernández L, Illnait J, Mendoza S, Gámez R, Fernández J, Mesa M.

Drugs Exp Clin Res. 2005;31 Suppl:31-44.

PMID:
16444910
11.

Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors.

Más R, Castaño G, Illnait J, Fernández L, Fernández J, Alemán C, Pontigas V, Lescay M.

Clin Pharmacol Ther. 1999 Apr;65(4):439-47.

PMID:
10223782
12.

Treatment of hypercholesterolemia in NIDDM with policosanol.

Torres O, Agramonte AJ, Illnait J, Más Ferreiro R, Fernández L, Fernández JC.

Diabetes Care. 1995 Mar;18(3):393-7.

PMID:
7555484
13.

Concomitant use of policosanol and beta-blockers in older patients.

Castaño G, Mas R, Gámez R, Fernández J, Illnait J, Fernández L, Mendoza S, Mesa M, Gutiérrez JA, López E.

Int J Clin Pharmacol Res. 2004;24(2-3):65-77.

PMID:
15689053
14.

Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk.

Castaño G, Más R, Fernández JC, Illnait J, Fernández L, Alvarez E.

J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M186-92.

PMID:
11253161
15.

[Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia].

Prat H, Román O, Pino E.

Rev Med Chil. 1999 Mar;127(3):286-94. Spanish.

PMID:
10436712
16.

Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia.

Frohlich J, Brun LD, Blank D, Campeau L, Crockford P, Curnew G, Dafoe W, Davignon J, Dufour R, Emery G, et al.

Can J Cardiol. 1993 Jun;9(5):405-12.

PMID:
8348392
17.

Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial.

Cubeddu LX, Cubeddu RJ, Heimowitz T, Restrepo B, Lamas GA, Weinberg GB.

Am Heart J. 2006 Nov;152(5):982.e1-5.

PMID:
17070175
18.

Effects of policosanol on postmenopausal women with type II hypercholesterolemia.

Castaño G, Más R, Fernández L, Fernández JC, Illnait J, López LE, Alvarez E.

Gynecol Endocrinol. 2000 Jun;14(3):187-95.

PMID:
10923280
19.

Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment.

Pons P, Rodríguez M, Robaina C, Illnait J, Más R, Fernández L, Fernández JC.

Int J Clin Pharmacol Res. 1994;14(1):27-33.

PMID:
7927958
20.

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.

Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, Black D.

Am J Cardiol. 1997 Jun 1;79(11):1475-81.

PMID:
9185636

Supplemental Content

Support Center